What is it about?
Augmentation of microchimerism in solid organ transplant recipients by donor bone marrow cells (DBMC) infusion to promote immune hyporesponsiveness and improve long-term allograft survival.
Featured Image
Why is it important?
Because of the main challenge for tolerance induction in allograft recipients in order to improve allograft function and survival without immunosuppressive therapy. The best and most feasible way to achieve this goal is chimerism-based protocols and our paper was designed based on this strategy.
Perspectives
the present observations as well as our previous reports on these patients are points to clinical efficacy of DBMC infusion even at low doses and without induction therapy which seems to be safer and more conservative approach in order to augment microchimerism and to affect a hyporeactive state in renal transplantation.
Dr Ghasem Solgi
Hamadan University of Medical Sciences
Read the Original
This page is a summary of: Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients, Chimerism, July 2013, Taylor & Francis,
DOI: 10.4161/chim.24719.
You can read the full text:
Contributors
The following have contributed to this page
